By: Benzinga
December 17, 2012 at 16:35 PM EST
Somaxon Reports Paladin Labs Wins Health Canada Approval of NDS for Silenor
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX ) today announced that its licensee Paladin Labs Inc. has received approval from Health Canada of Paladin's New Drug Submission (NDS) for Silenor^® (doxepin) for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal awakening and/or early morning awakenings.(c) 2012 Benzinga.com. Benzinga does not provide investment
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here